{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:21:39Z","timestamp":1794262899555,"version":"4.9.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-16-096"],"award-info":[{"award-number":["BCRF-16-096"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["microbone"],"award-info":[{"award-number":["microbone"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2021,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bone metastasis remains a major cause of mortality and morbidity in breast cancer. Therefore, there is an urgent need to better select high-risk patients in order to adapt patient\u2019s treatment and prevent bone recurrence. Here, we found that integrin alpha5 (ITGA5) was highly expressed in bone metastases, compared to lung, liver, or brain metastases. High\n                    <jats:italic>ITGA5<\/jats:italic>\n                    expression in primary tumors correlated with the presence of disseminated tumor cells in bone marrow aspirates from early stage breast cancer patients (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009268;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.039).\n                    <jats:italic>ITGA5<\/jats:italic>\n                    was also predictive of poor bone metastasis-free survival in two separate clinical data sets (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009855, HR\u2009=\u20091.36,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.018 and\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009427, HR\u2009=\u20091.62,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.024). This prognostic value remained significant in multivariate analysis (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.028). Experimentally,\n                    <jats:italic>ITGA5<\/jats:italic>\n                    silencing impaired tumor cell adhesion to fibronectin, migration, and survival.\n                    <jats:italic>ITGA5<\/jats:italic>\n                    silencing also reduced tumor cell colonization of the bone marrow and formation of osteolytic lesions in vivo. Conversely,\n                    <jats:italic>ITGA5<\/jats:italic>\n                    overexpression promoted bone metastasis. Pharmacological inhibition of ITGA5 with humanized monoclonal antibody M200 (volociximab) recapitulated inhibitory effects of\n                    <jats:italic>ITGA5<\/jats:italic>\n                    silencing on tumor cell functions in vitro and tumor cell colonization of the bone marrow in vivo. M200 also markedly reduced tumor outgrowth in experimental models of bone metastasis or tumorigenesis, and blunted cancer-associated bone destruction. ITGA5 was not only expressed by tumor cells but also osteoclasts. In this respect, M200 decreased human osteoclast-mediated bone resorption in vitro. Overall, this study identifies ITGA5 as a mediator of breast-to-bone metastasis and raises the possibility that volociximab\/M200 could be repurposed for the treatment of ITGA5-positive breast cancer patients with bone metastases.\n                  <\/jats:p>","DOI":"10.1038\/s41388-020-01603-6","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T13:03:46Z","timestamp":1610111026000},"page":"1284-1299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions"],"prefix":"10.1038","volume":"40","author":[{"given":"Francesco","family":"Pantano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Croset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keltouma","family":"Driouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9506-942X","authenticated-orcid":false,"given":"Natalia","family":"Bednarz-Knoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3536-7630","authenticated-orcid":false,"given":"Michele","family":"Iuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Ribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Bonnelye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6862-0888","authenticated-orcid":false,"given":"Harriet","family":"Wikman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Geraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Bonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0673-1272","authenticated-orcid":false,"given":"Sonia","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saw See","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4368-4866","authenticated-orcid":false,"given":"Sofia","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Tonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0149-4463","authenticated-orcid":false,"given":"Philippe","family":"Cl\u00e9zardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"1603_CR1","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1373\/clinchem.2008.110056","volume":"54","author":"MJ Duffy","year":"2008","unstructured":"Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin Chem. 2008;54:1770\u20139.","journal-title":"Clin Chem"},{"key":"1603_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","volume":"6","author":"RE Coleman","year":"2020","unstructured":"Coleman RE, Croucher PI, Padhani AR, Cl\u00e9zardin P, Chow E, Fallon M, et al. Bone metastases. Nat Rev Dis Prim. 2020;6:83.","journal-title":"Nat Rev Dis Prim"},{"key":"1603_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/14653240310000065","volume":"5","author":"G Wiedswang","year":"2003","unstructured":"Wiedswang G, Borgen E, Karesen R, Naume B. Detection of isolated tumor cells in BM from breast-cancer patients: significance of anterior and posterior iliac crest aspirations and the number of mononuclear cells analyzed. Cytotherapy. 2003;5:40\u20135.","journal-title":"Cytotherapy"},{"key":"1603_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/NEJM200002243420801","volume":"342","author":"S Braun","year":"2000","unstructured":"Braun S, Pantel K, M\u00fcller P, Janni W, Hepp F, Kentenich CR, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000;342:525\u201333.","journal-title":"N Engl J Med"},{"key":"1603_CR5","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrc2256","volume":"7","author":"JA Aguirre-Ghiso","year":"2007","unstructured":"Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7:834\u201346.","journal-title":"Nat Rev Cancer"},{"key":"1603_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrc3820","volume":"14","author":"C Alix-Panabi\u00e8res","year":"2014","unstructured":"Alix-Panabi\u00e8res C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14:623\u201331.","journal-title":"Nat Rev Cancer"},{"issue":"Suppl 1","key":"1603_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1869","volume":"10","author":"T Fehm","year":"2008","unstructured":"Fehm T, M\u00fcller V, Alix-Panabi\u00e8res C, Pantel K. Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. Breast Cancer Res. 2008;10 Suppl 1:S1.","journal-title":"Breast Cancer Res"},{"key":"1603_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature20785","volume":"540","author":"H Hosseini","year":"2016","unstructured":"Hosseini H, Obradovi\u0107 MMS, Hoffmann M, Harper KL, Sosa MS, Werner-Klein M, et al. Early dissemination seeds metastasis in breast cancer. Nature. 2016;540:552\u20138.","journal-title":"Nature"},{"key":"1603_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9\u201322.","journal-title":"Nat Rev Cancer"},{"key":"1603_CR10","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1158\/0008-5472.CAN-10-3453","volume":"71","author":"L Qin","year":"2011","unstructured":"Qin L, Chen X, Wu Y, Feng Z, He T, Wang L, et al. Steroid receptor coactivator-1 upregulates integrin \u03b15 expression to promote breast cancer cell adhesion and migration. Cancer Res. 2011;71:1742\u201351.","journal-title":"Cancer Res"},{"key":"1603_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1006\/excr.1996.3405","volume":"230","author":"D Van der Velde-Zimmermann","year":"1997","unstructured":"Van der Velde-Zimmermann D, Verdaasdonk MA, Rademakers LH, De Weger RA, Van den Tweel JG, Joling P. Fibronectin distribution in human bone marrow stroma: matrix assembly and tumor cell adhesion via alpha5 beta1 integrin. Exp Cell Res. 1997;230:111\u201320.","journal-title":"Exp Cell Res"},{"key":"1603_CR12","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1158\/0008-5472.CAN-03-3853","volume":"64","author":"R Korah","year":"2004","unstructured":"Korah R, Boots M, Wieder R. Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res. 2004;64:4514\u201322.","journal-title":"Cancer Res"},{"key":"1603_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1158\/2159-8290.CD-15-1183","volume":"6","author":"MJ Oudin","year":"2016","unstructured":"Oudin MJ, Jonas O, Kosciuk T, Broye LC, Guido BC, Wyckoff J, et al. Tumor cell-driven extracellular matrix remodeling drives haptotaxis during metastatic progression. Cancer Discov. 2016;6:516\u201331.","journal-title":"Cancer Discov"},{"key":"1603_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10549-016-3844-6","volume":"157","author":"H Yao","year":"2016","unstructured":"Yao H, Veine DM, Livant DL. Therapeutic inhibition of breast cancer bone metastasis progression and lung colonization: breaking the vicious cycle by targeting \u03b15\u03b21 integrin. Breast Cancer Res Treat. 2016;157:489\u2013501.","journal-title":"Breast Cancer Res Treat"},{"key":"1603_CR15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1158\/1541-7786.MCR-16-0338","volume":"15","author":"JA Ju","year":"2017","unstructured":"Ju JA, Godet I, Ye IC, Byun J, Jayatilaka H, Lee SJ, et al. Hypoxia selectively enhances integrin \u03b1(5)\u03b2(1) receptor expression in breast cancer to promote metastasis. Mol Cancer Res. 2017;15:723\u201334.","journal-title":"Mol Cancer Res"},{"key":"1603_CR16","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1158\/1535-7163.MCT-06-0100","volume":"5","author":"P Khalili","year":"2006","unstructured":"Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006;5:2271\u201380.","journal-title":"Mol Cancer Ther"},{"key":"1603_CR17","doi-asserted-by":"publisher","first-page":"5821","DOI":"10.1158\/0008-5472.CAN-06-4499","volume":"67","author":"Y Zhao","year":"2007","unstructured":"Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, et al. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res. 2007;67:5821\u201330.","journal-title":"Cancer Res"},{"key":"1603_CR18","doi-asserted-by":"publisher","first-page":"7924","DOI":"10.1158\/1078-0432.CCR-08-0378","volume":"14","author":"AD Ricart","year":"2008","unstructured":"Ricart AD, Tolcher AW, Liu G, Holen K, Schwartz G, Albertini M, et al. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res. 2008;14:7924\u20139.","journal-title":"Clin Cancer Res"},{"key":"1603_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1517\/14712598.2012.646985","volume":"12","author":"S Almokadem","year":"2012","unstructured":"Almokadem S, Belani CP. Volociximab in cancer. Expert Opin Biol Ther. 2012;12:251\u20137.","journal-title":"Expert Opin Biol Ther"},{"key":"1603_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ygyno.2010.12.362","volume":"121","author":"KM Bell-McGuinn","year":"2011","unstructured":"Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, et al. A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol. 2011;121:273\u20139.","journal-title":"Gynecol Oncol"},{"key":"1603_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/annonc\/mds281","volume":"24","author":"B Besse","year":"2013","unstructured":"Besse B, Tsao LC, Chao DT, Fang Y, Soria JC, Almokadem S, et al. Phase Ib safety and pharmacokinetic study of volociximab, an anti-alpha5beta1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol. 2013;24:90\u20136.","journal-title":"Ann Oncol"},{"key":"1603_CR22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.tranon.2018.01.021","volume":"11","author":"T Zuo","year":"2018","unstructured":"Zuo T, Shan J, Liu Y, Xie R, Yu X, Wu C. EFEMP2 mediates GALNT14-dependent breast cancer cell invasion. Transl Oncol. 2018;11:346\u201352.","journal-title":"Transl Oncol"},{"key":"1603_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-194","volume":"14","author":"MS Jami","year":"2014","unstructured":"Jami MS, Hou J, Liu M, Varney ML, Hassan H, Dong J, et al. Functional proteomic analysis reveals the involvement of KIAA1199 in breast cancer growth, motility and invasiveness. BMC Cancer. 2014;14:194.","journal-title":"BMC Cancer"},{"key":"1603_CR24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.bbrc.2018.03.007","volume":"498","author":"Z Wu","year":"2018","unstructured":"Wu Z, Wang T, Fang M, Huang W, Sun Z, Xiao J, et al. MFAP5 promotes tumor progression and bone metastasis by regulating ERK\/MMP signaling pathways in breast cancer. Biochem Biophys Res Commun. 2018;498:495\u2013501.","journal-title":"Biochem Biophys Res Commun"},{"key":"1603_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162933","volume":"11","author":"LC Fan","year":"2016","unstructured":"Fan LC, Jeng YM, Lu YT, Lien HC. SPOCK1 is a novel transforming growth factor-\u03b2-induced myoepithelial marker that enhances invasion and correlates with poor prognosis in breast cancer. PLoS ONE. 2016;11:e0162933.","journal-title":"PLoS ONE"},{"key":"1603_CR26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1083\/jcb.201108143","volume":"197","author":"J Pignatelli","year":"2012","unstructured":"Pignatelli J, Tumbarello DA, Schmidt RP, Turner CE. Hic-5 promotes invadopodia formation and invasion during TGF-\u03b2-induced epithelial-mesenchymal transition. J Cell Biol. 2012;197:421\u201337.","journal-title":"J Cell Biol"},{"key":"1603_CR27","first-page":"772","volume":"5","author":"ZZ Zhang","year":"2015","unstructured":"Zhang ZZ, Hua R, Zhang JF, Zhao WY, Zhao EH, Tu L, et al. TEM7 (PLXDC1), a key prognostic predictor for resectable gastric cancer, promotes cancer cell migration and invasion. Am J Cancer Res. 2015;5:772\u201381.","journal-title":"Am J Cancer Res"},{"key":"1603_CR28","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/jnci\/djr290","volume":"103","author":"S Sin","year":"2011","unstructured":"Sin S, Bonin F, Petit V, Meseure D, Lallemand F, Bi\u00e8che I, et al. Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis. J Natl Cancer Inst. 2011;103:1323\u201337.","journal-title":"J Natl Cancer Inst"},{"key":"1603_CR29","doi-asserted-by":"publisher","first-page":"26789","DOI":"10.18632\/oncotarget.4628","volume":"6","author":"N Bednarz-Knoll","year":"2015","unstructured":"Bednarz-Knoll N, Nasta\u0142y P, \u017baczek A, Stoupiec MG, Riethdorf S, Wikman H, et al. Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression. Oncotarget. 2015;6:26789\u2013803.","journal-title":"Oncotarget"},{"key":"1603_CR30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1089\/scd.1.1994.3.165","volume":"3","author":"K Pantel","year":"1994","unstructured":"Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother. 1994;3:165\u201373.","journal-title":"J Hematother"},{"key":"1603_CR31","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1158\/0008-5472.CAN-14-3728","volume":"75","author":"K Bartkowiak","year":"2015","unstructured":"Bartkowiak K, Kwiatkowski M, Buck F, Gorges TM, Nilse L, Assmann V, et al. Disseminated tumor cells persist in the bone marrow of breast cancer patients through sustained activation of the unfolded protein response. Cancer Res. 2015;75:5367\u201377.","journal-title":"Cancer Res"},{"key":"1603_CR32","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","volume":"10","author":"RM Neve","year":"2006","unstructured":"Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515\u201327.","journal-title":"Cancer Cell"},{"key":"1603_CR33","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1096\/fj.01-0911fje","volume":"16","author":"I P\u00e9cheur","year":"2002","unstructured":"P\u00e9cheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J. 2002;16:1266\u20138.","journal-title":"FASEB J"},{"key":"1603_CR34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","volume":"18","author":"H Hamidi","year":"2018","unstructured":"Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 2018;18:533\u201348.","journal-title":"Nat Rev Cancer"},{"key":"1603_CR35","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jbmr.5650080503","volume":"8","author":"DE Hughes","year":"1993","unstructured":"Hughes DE, Salter DM, Dedhar S, Simpson R. Integrin expression in human bone. J Bone Min Res. 1993;8:527\u201333.","journal-title":"J Bone Min Res"},{"key":"1603_CR36","doi-asserted-by":"publisher","first-page":"12520","DOI":"10.18632\/oncotarget.3724","volume":"6","author":"M Iuliani","year":"2015","unstructured":"Iuliani M, Pantano F, Buttigliero C, Fioramonti M, Bertaglia V, Vincenzi B, et al. Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. Oncotarget. 2015;6:12520\u20138.","journal-title":"Oncotarget"},{"key":"1603_CR37","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","volume":"28","author":"H Kennecke","year":"2010","unstructured":"Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271\u20137.","journal-title":"J Clin Oncol"},{"key":"1603_CR38","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/sj.bjc.6603720","volume":"96","author":"JA Anderson","year":"2007","unstructured":"Anderson JA, Grabowska AM, Watson SA. PTHrP increases transcriptional activity of the integrin subunit alpha5. Br J Cancer. 2007;96:1394\u2013403.","journal-title":"Br J Cancer"},{"key":"1603_CR39","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1158\/0008-5472.CAN-06-4100","volume":"67","author":"Y Imanishi","year":"2007","unstructured":"Imanishi Y, Hu B, Jarzynka MJ, Guo P, Elishaev E, Bar-Joseph I, et al. Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway. Cancer Res. 2007;67:4254\u201363.","journal-title":"Cancer Res"},{"key":"1603_CR40","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.1158\/0008-5472.CAN-17-3058","volume":"78","author":"M Croset","year":"2018","unstructured":"Croset M, Pantano F, Kan CWS, Bonnelye E, Descotes F, Alix-Panabi\u00e8res C, et al. MicroRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes. Cancer Res. 2018;78:5259\u201373.","journal-title":"Cancer Res"},{"key":"1603_CR41","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/ncb2767","volume":"15","author":"CM Ghajar","year":"2013","unstructured":"Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, et al. The perivascular niche regulates breast tumor dormancy. Nat Cell Biol. 2013;15:807\u201317.","journal-title":"Nat Cell Biol"},{"key":"1603_CR42","doi-asserted-by":"publisher","first-page":"29380","DOI":"10.1074\/jbc.272.46.29380","volume":"272","author":"KO Simon","year":"1997","unstructured":"Simon KO, Nutt EM, Abraham DG, Rodan GA, Duong LT. The alphavbeta3 integrin regulates alpha5beta1-mediated cell migration toward fibronectin. J Biol Chem. 1997;272:29380\u20139.","journal-title":"J Biol Chem"},{"key":"1603_CR43","doi-asserted-by":"publisher","first-page":"ra15","DOI":"10.1126\/scisignal.2004751","volume":"7","author":"HH Truong","year":"2014","unstructured":"Truong HH, Xiong J, Ghotra VP, Nirmala E, Haazen L, Le D\u00e9v\u00e9dec SE, et al. beta1 integrin inhibition elicits a prometastatic switch through the TGFbeta-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer. Sci Signal. 2014;7:ra15.","journal-title":"Sci Signal"},{"key":"1603_CR44","doi-asserted-by":"publisher","first-page":"18587","DOI":"10.1073\/pnas.0812334106","volume":"106","author":"Z Hamidouche","year":"2009","unstructured":"Hamidouche Z, Fromigu\u00e9 O, Ringe J, H\u00e4upl T, Vaudin P, Pag\u00e8s JC, et al. Priming integrin alpha5 promotes human mesenchymal stromal cell osteoblast differentiation and osteogenesis. Proc Natl Acad Sci USA. 2009;106:18587\u201391.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 2","key":"1603_CR45","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1038\/modpathol.2010.33","volume":"23","author":"SJ Schnitt","year":"2010","unstructured":"Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol. 2010;23 Suppl 2:S60\u20134.","journal-title":"Mod Pathol"},{"key":"1603_CR46","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10549-011-1619-7","volume":"132","author":"JC Harrell","year":"2012","unstructured":"Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, et al. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat. 2012;132:523\u201335.","journal-title":"Breast Cancer Res Treat"},{"key":"1603_CR47","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.1158\/0008-5472.CAN-08-0436","volume":"68","author":"T Landemaine","year":"2008","unstructured":"Landemaine T, Jackson A, Bellahc\u00e8ne A, Rucci N, Sin S, Abad BM, et al. A six-gene signature predicting breast cancer lung metastasis. Cancer Res. 2008;68:6092\u20139.","journal-title":"Cancer Res"},{"key":"1603_CR48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ccr.2009.05.017","volume":"16","author":"XH-F Zhang","year":"2009","unstructured":"Zhang XH-F, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell. 2009;16:67\u201378.","journal-title":"Cancer Cell"},{"key":"1603_CR49","first-page":"1652","volume":"61","author":"I Bieche","year":"2001","unstructured":"Bieche I, Parfait B, Le Doussal V, Olivi M, Rio MC, Lidereau R, et al. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Res. 2001;61:1652\u20138.","journal-title":"Cancer Res"},{"key":"1603_CR50","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/path.3956","volume":"226","author":"L Lehtinen","year":"2012","unstructured":"Lehtinen L, Vainio P, Wikman H, Reemts J, Hilvo M, Issa R, et al. 15-Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells. J Pathol. 2012;226:674\u201386.","journal-title":"J Pathol"},{"key":"1603_CR51","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1359\/jbmr.2001.16.11.2027","volume":"16","author":"O Peyruchaud","year":"2001","unstructured":"Peyruchaud O, Winding B, P\u00e9cheur I, Serre CM, Delmas P, Cl\u00e9zardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Min Res. 2001;16:2027\u201334.","journal-title":"J Bone Min Res"},{"key":"1603_CR52","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/jbmr.2215","volume":"29","author":"M Croset","year":"2014","unstructured":"Croset M, Goehrig D, Frackowiak A, Bonnelye E, Ansieau S, Puisieux A, et al. TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J Bone Min Res. 2014;29:1886\u201399.","journal-title":"J Bone Min Res"},{"key":"1603_CR53","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1158\/0008-5472.CAN-15-2621","volume":"77","author":"C Reynaud","year":"2017","unstructured":"Reynaud C, Ferreras L, Di Mauro P, Di Mauro P, Kan C, Croset M, et al. Lysyl oxidase is a strong determinant of tumor cell colonization in bone. Cancer Res. 2017;77:268\u201378.","journal-title":"Cancer Res"},{"key":"1603_CR54","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1083\/jcb.153.5.971","volume":"153","author":"E Bonnelye","year":"2001","unstructured":"Bonnelye E, Merdad L, Kung V, Aubin JE. The orphan nuclear estrogen receptor-related receptor alpha (ERRalpha) is expressed throughout osteoblast differentiation and regulates bone formation in vitro. J Cell Biol. 2001;153:971\u201384.","journal-title":"J Cell Biol"},{"key":"1603_CR55","doi-asserted-by":"publisher","first-page":"e8918","DOI":"10.1371\/journal.pone.0008918","volume":"5","author":"E Cerami","year":"2010","unstructured":"Cerami E, Demir E, Schultz N, Taylor BS, Sander C. Automated network analysis identifies core pathways in glioblastoma. PLoS ONE. 2010;5:e8918","journal-title":"PLoS ONE"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01603-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01603-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01603-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T11:17:59Z","timestamp":1676027879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01603-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,2,18]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1038\/s41388-020-01603-6","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"10 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}